Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Clinical Lymphoma|July 27, 2002
Proteasome inhibitors in the treatment of B-cell malignanciesDavid SchenkeinCancer Research|March 17, 2007
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell linesSandra J Strauss, Karen Higginbottom, Simone Jüliger, et al.Expert Review of Anticancer Therapy|February 25, 2003
Antibody-based therapeutics in oncologyJeffreys Ross, Karen Gray, David Schenkein, et al.International Journal of Cancer|December 21, 2004
Bortezomib is an efficient agent in plasma cell leukemiasAzucena Esparís-Ogando, Adrián Alegre, Beatriz Aguado, et al.British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.British Journal of Haematology|June 15, 2005
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaHeather E Oakervee, Rakesh Popat, Nicola Curry, et al.Blood|July 16, 2005
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaPaul Gerard Guy Richardson, Bart Barlogie, James Berenson, et al.British Journal of Haematology|August 3, 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?John Gerecitano, Andre Goy, John Wright, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Hank H Yang, Karen Sadler, et al.Pageof 2